Skip to main content

Table 3 Estimated marginal means, standard error, and pairwise comparisons of timepoints for the pooled sample

From: Pain-guided activity modification during treatment for patellar tendinopathy: a feasibility and pilot randomized clinical trial

Category Outcome Baseline 6 weeks 12 weeksa p values
M SE M SE M SE Baseline to 6 weeks Baseline to 12 weeks 6 weeks to 12 weeks
Symptoms VISA-P (points) 59.6 3.8 68.8 3.8 75.6 4.0 0.043 0.001 0.136
Palpatory pain (NPRS) 3.8 0.5 2.8 0.6 2.3 0.6 0.010 0.006 0.347
Quality of life KOOS-QOL (%) 42.4 3.7 58.9 3.7 68.0 3.9 < 0.001 < 0.001 0.029
Psychological factors TSK (points) 36.4 1.1 35.8 1.1 34.2 1.1 0.448 0.015 0.075
DASS-21 (points) 3.2 1.0 3.4 1.1 5.6 1.1 0.847 0.040 0.061
PCS (points) b 2.0 6.0 1.0 2.0 1.0 3.0
Morphology Thickness (mm) 6.9 0.5 6.8 0.5 6.6 0.6 0.427 0.329 0.678
CSA (mm2) 111.9 11.0 118.0 10.6 118.0 12.0 0.355 0.443 1.000
Mechanical properties Shear Modulus (kPa) 70.6 6.3 77.1 6.2 79.8 9.2 0.427 0.391 0.796
Viscosity (Pa*sec) 31.6 2.4 29.7 2.3 33.0 3.1 0.396 0.628 0.268
Lower extremity function CMJ height (cm) 12.1 1.2 13.3 1.2 13.7 1.3 0.033 0.045 0.620
Drop CMJ height (cm) 13.4 1.2 13.9 1.3 13.4 1.4 0.423 0.953 0.588
Quadriceps muscle performance MVIC (N) 860.9 56.7 995.9 60.0 1053.4 85.6 0.138 0.082 0.601
CAR (%) 80.6 3.3 84.1 3.8 90.7 4.9 0.440 0.076 0.250
  1. CSA Cross-sectional area, CMJ Counter-movement jump, MVIC Maximal voluntary isometric contraction, CAR Central activation ratio, NPRS Numeric pain rating scale
  2. Bold indicates statistically significant differences between timepoints
  3. an = 14 for patient reported outcome measures at 12 weeks (VISA-P, TSK, PCS, DASS-21) due to participant drop-out. n = 8 for all other measures at 12 weeks due to inability to complete in-person follow-ups because of COVID-19
  4. bPCS did not meet assumption of linearity so model significance was not tested and values reported are median and interquartile range, respectively